Clinical trials: Demyelinating Diseases
Relapsing Multiple Sclerosis
A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)
This study aims to examine the efficacy and safety of obexelimab in participants with relapsing multiple sclerosis
- Trial name
- NCT06564311
- Testing
- Obexelimab
- Where
- 47 sites in United States, Austria and 10 more
- Volunteers
- 93 people
- Sponsor
- Zenas BioPharma (USA), LLC
Relapsing Remitting Multiple Sclerosis
Atorvastatin in Relapsing-Remitting Multiple Sclerosis
A phase II open-label baseline-to-treatment trial was designed to evaluate the safety, tolerability and efficacy of orally administered atorvastatin in patients with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- NCT00616187
- Testing
- interferon beta treatment to add-on atorvastatin treatment, untreated to atorvastatin treatment
- Volunteers
- 41 people
- Sponsor
- Charite University, Berlin, Germany
Multiple Sclerosis, Fatigue
Ketamine for Treatment of MS Fatigue
Multiple sclerosis (MS) is an inflammatory, demyelinating and degenerative disease of the central nervous system and, after trauma, is the most common cause of disability in young adults, affecting more than 400,000 individuals…
- Trial name
- NCT03500289
- Testing
- Ketamine, Midazolam
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Johns Hopkins University
Multiple Sclerosis, Pain
Management of Pain in Persons With Multiple Sclerosis
The purpose of this study is to see if treatments that include components of self-hypnosis training and cognitive behavioral therapy (CBT) can help decrease pain in people with MS.
- Trial name
- NCT00621374
- Testing
- Cognitive Behavioral Therapy (CBT) +Hypnosis (HYP), Cognitive Behavioral Therapy (CBT), Self-Hypnosis Training (HYP)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Washington
Multiple Sclerosis
Effects of Antiviral Therapies on Epstein-Barr Virus Replication
This research study is being performed to find out if Truvada (tenofovir/emtricitabine), an antiviral drug with activity against the Epstein Barr virus (EBV), can reduce EBV levels in saliva and blood in people with multiple…
- Trial name
- NCT05957913
- Testing
- Truvada (tenofovir/emtricitabine)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Multiple Sclerosis
JC-Virus (JCV) Antibody Program
The primary objective is to define the prevalence of serum anti-JCV antibody in relapsing multiple sclerosis (MS) participants receiving Tysabri® (natalizumab) or being considered for such treatment.
- Trial name
- STRATIFY-1 (NCT01070823)
- Testing
- Tysabri® (natalizumab)
- Where
- 11 sites in United States
- Volunteers
- 1,096 people
- Sponsor
- Biogen
Neuromyelitis Optica Spectrum Disorder, NMOSD
A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
This study will primarily evaluate the pharmacokinetics of satralizumab in pediatric patients aged 2-11 years with anti-aquaporin-4 (AQP4) antibody seropositive neuromyelitis optica spectrum disorder (NMOSD).
- Trial name
- SAkuraSun (NCT05199688)
- Testing
- Satralizumab
- Where
- 14 sites in United States, Argentina and 7 more
- Volunteers
- 8 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis
Prospective Stratification of Infectious Risks in Multiple Sclerosis
This monocentric study is to identify factors that increase the susceptibility for infections and establish a questionnaire-based infection score that allows a prospective stratification for infectious risks in patients with…
- Trial name
- InRIMS (NCT04036097)
- Testing
- MS-adapted AWIS questionnaire (MS-AWIS), infection diary (MS-AWIS diary)
- Where
- Switzerland
- Volunteers
- 298 people
- Sponsor
- University Hospital, Basel, Switzerland
Multiple Sclerosis
IL-11 in the Development of Multiple Sclerosis
Since the last submission, the investigator have further characterized the potential of IL--11 to induce encephalitogenic CD4+IL--17A+, IL--21+ and GM--CSF+ cells, which upon passive transfer induced severe RREAE with…
- Trial name
- NCT03735823
- Testing
- No intervention, just collect blood samples and CSF samples
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Multiple Sclerosis, Fatigue
The Effect of the Nurses Support Program on Fatigue in MS Patient
The research will be carried out as a randomized controlled experimental study to examine the effect of a nursing support program supported by a Web-based education program on the management of fatigue symptoms of patients who…
- Conditions
- Multiple Sclerosis, Fatigue, Sleep Hygiene, Quality of Life
- Trial name
- NCT06166043
- Testing
- NURSE FOLLOW-UP PROGRAM SUPPORTED WITH WEB-BASED EDUCATION
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Istanbul University - Cerrahpasa
Multiple Sclerosis, Relapsing-remitting
Assessment of Lesion Activity Analysis in the Avonex- Steroid Azathioprine (ASA) Study
To examine short- and long-term value of appearance of new active lesions in predicting extent of cortical and subcortical deep gray matter (SDGM) atrophy over 5 years in ASA (Avonex- Steroid-Azathioprine)study.
- Trial name
- ASA (NCT01628315)
- Testing
- MRI
- Where
- United States
- Volunteers
- 159 people
- Sponsor
- University at Buffalo
Multiple Sclerosis
Stem Cells in Rapidly Evolving Active Multiple Sclerosis
This is a randomised, double-blind crossover study to study the effect of intravenous treatment with autologous (derived from the individuals themselves) mesenchymal stem cells (MSCs) in patients with multiple sclerosis (MS).
- Trial name
- STREAMS (NCT01606215)
- Testing
- Mesenchymal stem cells
- Where
- United Kingdom
- Volunteers
- 21 people
- Sponsor
- Imperial College London
Multiple Sclerosis, Relapsing-Remitting, Clinically Isolated Syndrome
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
The purpose of this study is to further evaluate the safety and efficacy of Tovaxin in the treatment of relapsing forms of multiple sclerosis.
- Trial name
- OLTERMS (NCT00595920)
- Testing
- Tovaxin
- Where
- 27 sites in United States
- Volunteers
- 116 people
- Sponsor
- Opexa Therapeutics, Inc.
Multiple Sclerosis
Effects of Fingolimod on Heart Rhythm and Heart Rate Variability in Patients With Multiple Sclerosis
The current study sought to prolong the observational interval after initiating medication with fingolimod and to measure the long-term effects of fingolimod on HR and HRV as an indicator of autonomic nervous system function in…
- Trial name
- FINGORHYMS (NCT03216915)
- Testing
- Gilenya®; Novartis Pharmaceuticals Corporation
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Autoimmune or Autoinflammatory Diseases, HIV
Study of the Humoral Response to SARS-CoV-2 Variants and of the Cellular Response After Vaccination Against COVID-19 in Immunocompromised People
Prospective, multicenter, non-comparative cohort study of immunocompromised people vaccinated against Covid-19 with the aim to know the humoral and cellular response to BNT162b2 vaccination against SARS-CoV-2 variants.
- Conditions
- Autoimmune or Autoinflammatory Diseases, HIV, Multiple Sclerosis, Solid Tumors or Cancers
- Trial name
- COVIVAC-ID (NCT04844489)
- Testing
- Blood samples for the study of the humoral response to SARS-CoV-2 variants and of the cellular response after vaccination against COVID-19
- Where
- France
- Volunteers
- 377 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Multiple Sclerosis
Internet-based MOTOmed Exercise to Reduce Spasticity and Improve Physical Function in Persons With Multiple Sclerosis
In an RCT, the effect of the MOTOmed movement trainer (Reck, Germany) on spasticity and physical function in pwMS with EDSS score between 4,5 and 7 is investigated.
- Trial name
- NCT03548974
- Testing
- Treatment group 1, Treatment group 2
- Volunteers
- 57 people
- Sponsor
- University of Erlangen-Nürnberg
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorders
Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders
The treatment protocol consisted of 12 mg/m2 MITO intravenous infusions every 3 months for 2 years. Dosage was adjusted according to side effects.
- Trial name
- NCT02021825
- Testing
- Mitoxantrone
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Xuanwu Hospital, Beijing
Multiple Sclerosis, Chronic Pain
MS Symptom Management Study
People with Multiple Sclerosis (MS) often have pain and/or fatigue. Unfortunately, available treatments provide inadequate relief for the majority of these individuals.
- Conditions
- Multiple Sclerosis, Chronic Pain, Fatigue
- Trial name
- ENHANCE (NCT02474940)
- Testing
- Intervention #1, Intervention #2, Intervention #3
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Washington
Multiple Sclerosis, Tremor
The Efficacy of Botulinum Toxin in Disabling Multiple Sclerosis (MS) Tremor
The incidence of tremor in Multiple Sclerosis (MS) has been estimated to affect up to 2/3rds of patients. Over half of the tremors involve the upper limb and frequently lead to further disability.
- Trial name
- NCT01018485
- Testing
- Botulinum Toxin Type A
- Where
- Australia
- Volunteers
- 30 people
- Sponsor
- Melbourne Health
Multiple Sclerosis
Smart Monitoring Assessing Spasticity-related Health
This observational study seeks to investigate the underlying of spasticity in patients with multiple sclerosis (MS) by employing multimodal monitoring techniques.
- Trial name
- SMASH (NCT06937723)
- Testing
- Device: Smartwatch (Withings Scanwatch)
- Where
- Germany
- Volunteers
- 46 people
- Sponsor
- Heinrich-Heine University, Duesseldorf